Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study

PURPOSE: Pasireotide long-acting release is a somatostatin analog that is indicated for treatment of patients with acromegaly. This analysis documents the safety of pasireotide long-acting release in patients with acromegaly enrolled in the ACCESS trial (ClinicalTrials.gov identifier: NCT01995734)....

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Udgivet i:	Endocrine
Main Authors:	Fleseriu, Maria, Rusch, Elisha, Geer, Eliza B.
Format:	Artigo
Sprog:	Inglês
Udgivet:	Springer US 2016
Fag:	Original Paper
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5225222/ https://ncbi.nlm.nih.gov/pubmed/27896545 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12020-016-1182-4
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study

Lignende værker